Randomized Phase 1b/2 Study of Nivolumab or Nivolumab Plus BMS-986253 in Combination with Intermittent Androgen Deprivation Therapy in Men with Hormone-Sensitive Prostate Cancer (MAGIC-8)
Study of Immunotherapy with Nivolumab or BMS-986253 Added to Degarelix in Patients with Prostate Cancer (MAGIC-8)
Sponsor: Bristol Myers Squibb
Enrolling: Male Patients Only
IRB Number: AAAR7949
U.S. Govt. ID: NCT03689699
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study is for patients with prostate cancer and that require treatment because their disease is now growing. The purpose of this study is to see whether immunotherapy with nivolumab added to degarelix or nivolumab and BMS-986253 added to degarelix is safe and can decrease the chance that the cancer will come back. Degarelix is a standard of care drug used for the treatment of prostate cancer that works by suppressing your testosterone. Approximately 60 individuals will be asked to participate in this study.
This study is closed
Mark Stein, MD
Do You Qualify?
Are you a male who is 18 years or older? Yes No
Do you have a diagnosis of prostatic adenocarcinoma? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator